The US-based START Center for Cancer Research (START) and OneOncology have collaborated to introduce three early-phase trial sites in the US.
The partners will launch START trial sites at the Los Angeles Cancer Network in California, the Astera Cancer Care in New Jersey, and the Center for Cancer and Blood Disorders in Texas.
The collaboration aims to expand access to cancer therapies among community practices, a sector in which a majority of cancer patients receive care but accessibility to early-phase trials remains limited.
It comes after START inaugurated a trial site at the Cancer & Hematology Centers in Michigan, which is also a OneOncology partner practice.
The expansion of sites across OneOncology’s partner practices is scheduled to begin in July this year, with their activations continuing into early next year.
Each practice will be integrated into START’s operational and research infrastructure for quick activation, trial execution and data quality.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOneOncology is a physician-led national oncology platform with a network of community-based oncology practices.
It has more than 1,750 providers, who care for nearly one million individuals every year across more than 565 areas.
OneOncology CEO Jeff Patton said: “Working with START allows our partner practices to extend their capabilities into groundbreaking early-phase research, providing access to new therapies traditionally reserved for academic centres.
“Together, we’re transforming the patient experience, bringing innovation closer to home and significantly impacting cancer outcomes nationwide.”
START is an early-phase oncology research network currently overseeing more than 700 early-phase trials, with ten trial sites worldwide and 31 principal investigators.
The network has been involved in the development and approval of more than 45 cancer therapies by the Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Last year, it partnered with the Fundación Rioja Salud foundation to broaden the reach of early-phase cancer trials in La Rioja, Spain.
